Biofrontera Inc. (BFRI)

Nasdaq: BFRI · Pharmaceutical Preparations · Woburn, MA · filing with the SEC since 2021

Full chart Alerts Compare

Grade4.2

◀ Past 3.9● Present 4.1▶ Future 4.6

1 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Biofrontera Inc.

Nine metrics read from its own filings, by tense

Headline grade

4.2/10

◀ Past3.930% of the headline

● Present4.140% of the headline

▶ Future4.630% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

3.9/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

1.5/10

Has it survived what it has been through?

12 warning events since 2021; the latest 2026-01-07.

weight 33% of this tense · 15th percentile among 497 sector filers · read for itself

From the record

Biofrontera Inc.'s filings since 2021 show 12 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 8 times, the latest 2026-01-07); an auditor change (8-K item 4.01, 3 times, the latest 2025-04-18); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2022-04-01) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

6.7/10

What has it actually done, year after year?

+17.2% a year over 6 filed years; profitable in 0 of 6.

weight 45% of this tense · 67th percentile among 323 sector filers · read for its customers

From the record

Biofrontera Inc.'s 6 filed years say what it did: revenue went from $19 million in fiscal 2020 to $42 million in fiscal 2025, up 17.2% a year; it rose in 5 of 5 years; it never fell from a peak; net income was positive in 0 of 6 of those years (its annual reports).

What it rests on

revenue growth over the filed span17.2%top 43% of its family
the share of years revenue rosetop 8% of its family
the share of filed years with a profitbottom 27% of its family
the deepest fall from a revenue peak0.0%top 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

2.0/10

How has it treated the people who own it?

SI estimate 2.0/10, confidence 35 of 100 (one part).

weight 22% of this tense · 20th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the bottom 20% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Biofrontera Inc.'s shareholder treatment is put at 2.0 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 20% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

4.1/1040% of the headline grade · 3 of 3 filed

Financial health

as filed

2.8/10

Is it financially healthy right now?

ROE -101%: lost 101¢ per shareholder dollar. Leverage 63%: owes 63¢ per asset dollar.

weight 45% of this tense · 28th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Biofrontera Inc. lost about 101 cents for every dollar of shareholders' money. Leverage: it owed about 63 cents per dollar of assets, and net share issuance: its share count grew 84.4% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 25% of its family
return on equitybottom 31% of its family
the share count against the year beforebottom 27% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

5.8/10

How strong is its position in its industry?

top 42% of 315 in its family; net margin -25.3%.

weight 33% of this tense · 58th percentile among 315 sector filers · read for its customers

From the record

Biofrontera Inc.'s standing among 315 graded names in its industry family: revenue of $42 million in fiscal 2025 ranks in the top 47% by size; a net margin of -25.3% ranks in the top 34%; revenue growth of 13.3% a year over the last 3 filed years ranks in the top 44% (its annual reports).

What it rests on

revenue against the family$41.7Mtop 47% of its family
net margin-25.3%top 34% of its family
three-year revenue growth13.3%top 44% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed

4.4/10

What are the people in charge doing?

bottom 44% of 315 in its family for leadership; chief executive since 2024.

weight 22% of this tense · 44th percentile among 315 sector filers · read for its shareholders

From the record

Biofrontera Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Luebbert, Hermann (CEO & Chairman, as filed), filing under that title since 2024-05-22, 2.5 years (bottom 28% of its family); the 8 officers and directors filing in the last fifteen months have been on the record a median of 4.3 years (bottom 27%); 2 officer or director changes were reported on Form 8-K since 2023-11-13, against the 8 people in charge now (top 23%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

officer and director changes on Form 8-K, against the people in charge2 in three years among 8 peopletop 23% of its family
the median years the people in charge have filed4.3 yearsbottom 27% of its family
the chief executive's years on the record2.5 yearsbottom 28% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

4.6/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed

3.9/10

How much room does it have to grow?

bottom 39% of 273 in its family for room to expand.

weight 45% of this tense · 39th percentile among 273 sector filers · read for itself

From the record

Biofrontera Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $6 million against no long-term debt tagged leaves 22.4% of its assets as net cash, bottom 44% of its family; cash from operations less capital spending is -32% of revenue (top 41%); research spending of 8.9% of revenue (bottom 13%) (its annual report).

What it rests on

cash less debt against assets22.4%bottom 44% of its family
cash from operations less capital spending against revenue-32.0%top 41% of its family
research spending against revenue8.9%bottom 13% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

5.3/10

What could actually drive growth from here?

top 47% of 306 in its family for growth drivers.

weight 33% of this tense · 53rd percentile among 306 sector filers · read for its customers

From the record

Biofrontera Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 13.3% a year over the last three filed years against 17.2% over all 6, slowing (bottom 46% of its family); the newest year grew 11.8% (top 45%); research spending grew 594.1% a year (top 1%); capital spending grew -62.5% a year (bottom 11%) (its annual reports). Biofrontera Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span-3.9 points a yearbottom 46% of its family
the newest year's revenue growth11.8%top 45% of its family
three-year growth of research spending594.1%top 1% of its family
three-year growth of capital spending-62.5%bottom 11% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

5.0/10

Did its newest year beat what its own record pointed to?

top 50% of 233 in its family for expectations against reality.

weight 22% of this tense · 50th percentile among 233 sector filers · read for its shareholders

From the record

Biofrontera Inc.'s newest year against its own record: revenue of $42 million in fiscal 2025 came in 2% below the $43 million its prior three years' pace pointed to (bottom 49% of its family); net income of $11 million against a prior three-year average of $13 million (top 48%); a net margin of -25.3% against -36.3% before (top 49%) (its annual reports).

What it rests on

revenue against the prior three years' pace-2.0%bottom 49% of its family
net income against the prior three years' average+18%top 48% of its family
net margin against its prior average+11.0 pointstop 49% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton BFRI · research, not advice